drugset / Trial / NCT00002826
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
Phase 2
Completed
36 enrolled
Eastern Cooperative Oncology Group
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with a chemotherapy drug may reduce resistance to the drug, and allow the tumor cells to be killed. PURPOSE: Phase II trial to study the effectiveness of PSC 883 and paclitaxel in treating women who have recurrent or metastatic breast cancer.
Timeline
- Start
- 1997-08-14
- Primary completion
- 2003-11
- Completion
- —
Publications
- Results Carlson RW, O'Neill A, Goldstein L, et al.: A phase II trial of PSC-833 modulation of multidrug resistance to paclitaxel in breast cancer: a pilot trial of the Eastern Cooperative Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-234, 2002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | valspodar | Protein / enzyme biologic | — | Oral |